Competing for the Last Mile of Vaccine R&D, mRNA Vaccines Become a Hot Spot for Competition

As of now, the total number of confirmed cases of COVID-19 worldwide has exceeded 72 million, and the number of deaths has exceeded 1.6 million. However, there is still no specific medicine for the treatment of COVID-19 in the world.

But what is worth looking forward to is that the COVID-19 vaccine research and development work carried out at the same time as the COVID-19 treatment drug research and development has achieved good results. A number of COVID-19 vaccines have entered phase III clinical trials worldwide, and clinical phase I/II results have been published, and also preliminarily shows the good safety and immunogenicity of the vaccine.

The COVID-19 vaccine research and development path is equipped with new mRNA technology to breakthrough!

There are currently multiple technological paths for the development of COVID-19 vaccines. Most of the traditional technology paths are inactivation, attenuation, and protein recombination technologies, and their applications are relatively mature. New technology platforms such as viral vector vaccines and nucleic acid vaccines (mRNA vaccines and DNA vaccines) that have emerged in recent years have opened up new directions for vaccine research and development.

Among them, mRNA vaccines are the third-generation vaccines developed after attenuated vaccines, inactivated vaccines, and subunit vaccines. Because of its unique advantages such as safety, effectiveness, and short R&D cycle, it has won the favor of pharmaceutical companies and a large amount of capital investment and has become one of the main technical routes for the COVID-19 vaccine research and development.

Figure 1: 5 research and development technology paths for the COVID-19 vaccine

The mechanism of action of the COVID-19 mRNA vaccine

Unlike traditional vaccines that directly introduce antigen proteins to stimulate the host’s immune response, mRNA vaccines are a safer new type of nucleic acid vaccine.

mRNA vaccines transmit the nucleic acid information of antigens into the human body, and the cells inside the body will respond accordingly. The cells inside the body will produce antigens consistent with its information based on this "portrait" to simulate virus infection, and the immune system can then produce an immune response against this. For the COVID-19 virus (SARS-CoV-2), the S protein on the spike is the most critical target antigen.

After vaccination, the mRNA encoding the spike protein (S protein) packaged in a lipid nanoparticle enters the cell and synthesizes the protein in the ribosome. The protein is broken down into smaller fragments (polypeptides) by the cellular proteasome or transported to the outside of the cell through the "transporter" Golgi apparatus.

The antigen peptide fragments enzymatically hydrolyzed in the cell form a complex with the major histocompatibility complex (MHC)-class I protein, which is expressed on the surface of the antigen-presenting cell and is recognized by the "detective" CD8+ T cells to induce the cell-mediated immune response.

On the other hand, the extracellular spike protein can be swallowed, pinocytosed, and broken down into smaller polypeptide fragments by different immune cells, forming complexes with MHC-II proteins, and expressed on the surface of antigen-presenting cells, recognized by CD4+ T cells and promote B cells to produce antigen-specific antibodies.

Advantages of mRNA vaccines

• High R&D efficiency

The mRNA vaccine synthesis and production process is relatively convenient. It can be completed within 1-2 months from vaccine design to sample preparation. The research and development cost is relatively low, and it is convenient for rapid capacity expansion.

• Short development cycle

The mRNA vaccine is produced through a cell-free in vitro transcription process. Compared with traditional vaccines, its production is easy and fast. In the case of the COVID-19 epidemic, the mRNA vaccine development cycle is expected to be shortened to about 1 year

• Good security

mRNA will not be integrated into the genome, can be expressed transiently, metabolized and eliminated by the body's natural mechanism, will not persist for a long time, and can avoid therapeutic mutations

• Good immunogenicity

mRNA has a certain self-adjuvant effect, can effectively activate the immune response, can produce more comprehensive humoral immunity and cellular immunity, and fight the virus through dual mechanisms

Table 1: Comparison of the characteristics of 5 types of vaccines

mRNA vaccines for COVID-19 in clinical development

As of October 29, 2020, the WHO COVID-19 vaccine progress sketch shows that a number of mRNA vaccines have entered clinical trials (see the table below), including the mRNA-1273 vaccine developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) and The BNT162b2 vaccine jointly developed by BioNTech, Pfizer and Fosun Pharma has entered Phase III clinical trials and is currently progressing smoothly.

Difficulties must be overcome in mRNA vaccine development

However, two major challenges related to the immunogenicity and stability of mRNA vaccines must be overcome to make it a viable clinical alternative to conventional vaccines.

• First, the mRNA chain in the vaccine may cause an unexpected immune response. To minimize this situation, the mRNA vaccine sequence has been optimized (including a variety of chemical modifications) to mimic the sequence produced by mammalian cells.
• Secondly, free mRNA will be rapidly degraded in the body, thereby weakening the immune function. Incorporating mRNA into lipid nanoparticles can improve stability and make it easier to enter cells.

These advances have made mRNA vaccines more widely used.

It is not clear which candidate COVID-19 vaccine will make it to the market first, and which vaccine approach will be most effective in the long run. However, clinical trial evidence to date shows that mRNA vaccines have great potential to become a new platform that is fast, safe, and efficient.

Related Articles

• mRNA vaccine delivery strategy
• SARS-CoV-2 is undergoing mutations. Does the vaccine still work?
• bioRxiv.: Scientists Find siRNA drugs that may inhibit SARS-CoV-2
• Cell Immunity: SARS-CoV-2 vaccines status
• Will the mRNA vaccine become the "savior" of COVID-19?
• mRNA-1647，the first infectious disease mRNA vaccine to enter the second phase of research

Competing for the Last Mile of Vaccine R&D, mRNA Vaccines Become a Hot Spot for Competition

- mg g kg ton

We recommend you to leave us your work email address so that we can serve you better. Please leave your organization information here if you don't have a work email address.

SUBMIT